Next Edge Bio-Tech Plus F (MCC214)

7.612 +0.12  +1.61% Jul 14 CAD
View Full Chart
Total Returns Chart

Key Stats

Net Asset Value 7.612
Turnover Ratio 208.8%
1 Year Fund Level Flows --

Performance & Returns

  Total Return Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M -1.98% -- --
3M 3.42% -- --
6M -5.70% -- --
YTD -6.21% -- --
1Y -23.27% -- --
3Y -9.61% -- --
5Y -6.58% -- --
10Y -- -- --
15Y -- -- --
20Y -- -- --
As of July 14, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 7.03% 7.03% 0.00%
Stock 86.94% 86.94% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 1.64% 1.64% 0.00%
Other 4.39% 4.39% 0.00%
As of March 31, 2020

Region Exposure

Americas 99.15%
North America 99.15%
Latin America 0.00%
Greater Europe 0.85%
United Kingdom 0.85%
Europe Developed 0.00%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.00%
As of March 31, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 95.69%
Industrials 0.00%
Real Estate 0.00%
Technology 4.31%
Utilities 0.00%
As of March 31, 2020

Stock Market Capitalization

Giant 0.00%
Large 0.00%
Medium 3.94%
Small 18.22%
Micro 77.84%
As of March 31, 2020

Stock Style Exposure

Large Cap Value 0.00%
Large Cap Blend 0.00%
Large Cap Growth 0.00%
Mid Cap Value 0.00%
Mid Cap Blend 0.00%
Mid Cap Growth 4.36%
Small Cap Value 7.89%
Small Cap Blend 48.62%
Small Cap Growth 39.13%
As of March 31, 2020
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
AQS.V Aequus Pharmaceuticals Inc 8.94% 0.085 +6.25%
MBX.TO Microbix Biosystems Inc 8.35% 0.32 +0.00%
ICO.V iCo Therapeutics Inc 4.38% 0.04 +0.00%
-- Warrant on Mri Interventions 4.07% -- --
SQD.V SQI Diagnostics Inc 3.66% 0.17 +9.68%
OPS.TO Opsens Inc 3.08% 0.70 +0.00%
ICPT Intercept Pharmaceuticals Inc 2.85% 44.72 +2.92%
CPRX Catalyst Pharmaceuticals Inc 2.09% 5.04 +1.61%
-- Antibe Therapeutics ([Wts/Rts]) 2.04% -- --
CVM.V CVR Medical Corp 2.03% 0.04 +0.00%
As of March 31, 2020
Advertisement

Basic Info

Investment Strategy
This Fund seeks short and long-term capital appreciation through the ownership of small and mid-capitalization biotechnology and healthcare companies based in Canada and the United States.
General
Security Type Mutual Fund
Oldest Share Symbol MCC224
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Prospectus Objective --
Fund Owner Firm Name Next Edge Capital Corp.
Benchmark Index
NASDAQ Biotechnology TR USD 60.00%
S&P/TSX Capped Health Care TR 40.00%
Reports
One Page Report Download

Manager Info

Name Tenure
Eden Rahim 5.59 yrs
Michael Bird 5.59 yrs

Share Classes

Symbol Share Class
MCC213 Commission-based Advice
MCC223 Commission-based Advice
MCC224 Fee-based Advice

Net Fund Flows

1M --
3M --
6M --
YTD --
1Y --
3Y --
5Y --
10Y --
Date Unavailable

Risk Info

Beta (5Y) 0.8099
Historical Sharpe Ratio (10Y) --
Historical Sortino (All) -0.1769
Daily Value at Risk (VaR) 1% (All) 4.18%
Monthly Value at Risk (VaR) 1% (All) 19.19%

Fundamentals

Dividend Yield TTM (7-14-20) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio 3.348
Weighted Average Price to Book Ratio 4.220
Weighted Median ROE --
Weighted Median ROA -25.32%
Forecasted Dividend Yield 0.00%
Forecasted PE Ratio 17.00
Forecasted Price to Sales Ratio 3.106
Forecasted Price to Book Ratio 3.360
Number of Holdings 62
As of March 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth 3.00%
Forecasted Book Value Growth -14.08%
Forecasted Cash Flow Growth -33.19%
Forecasted Earnings Growth 9.60%
Forecasted Revenue Growth -78.99%
As of March 31, 2020

Comparables

Edit

Attributes

Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment 5000.00 CAD
Minimum Subsequent Investment 1000.00 CAD
Fees
Actual 12B-1 Fee --
Actual Management Fee 1.25%
Administration Fee --
Performance Fee 20.00%
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
Key Dates
Inception Date 12/1/2014
Termination Date
Last Annual Report Date 12/31/2019
Last Prospectus Date
Attributes
Exchange Traded Share No
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP Yes
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.